GsMtx-4
Also known as: Grammostola mechanotoxin-4, Grammostola spatulata mechanotoxin 4, GsMTx-4, GsMTx4, Piezo channel inhibitor peptide
Source GsMtx-4 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
GsMTx-4 is a 34‑amino‑acid peptide isolated from the venom of the tarantula Grammostola spatulata. It blocks mechanosensitive ion channels and is used experimentally to study mechanotransduction and as a lead for neuroprotective and cardioprotective therapies.
Mechanism of Action
binds to lipid membrane and inhibits stretch‑activated mechanosensitive ion channels (e.g., PIEZO1/2, TREK‑1) thereby altering channel gating
Routes of Administration
Goals & Uses
- Muscular dystrophy (Duchenne) treatmentNeuromuscular DiseaseLow
- Research tool – mechanotransduction studiesResearchHigh
- Cardioprotection during ischemiaCardiovascular / CardioprotectionLow
- Atrial fibrillation suppressionCardiovascularLow
- Neuroprotection after traumatic brain injuryNeurologicalLow
- Neuropathic pain reliefPain / NeurologyModerate
- Pulmonary arterial hypertensionCardiovascular / PulmonaryLow
Contraindications
- Known hypersensitivity to spider venom peptidesAllergy / ImmunologyHigh
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Human clinical useRegulatoryHigh
Adverse Effects
- Cardiovascular depressionCardiovascularUnknown
- HypotensionCardiovascularUncommonLow blood pressure
- Immune/allergic reactionImmunologicalUnknown
- Off-target channel inhibitionPharmacologicalUncommon
Drug Interactions
- Other mechanosensitive channel modulatorsLow
Population Constraints
- Pregnant or lactating individualsReproductiveRelative
- Pediatric populationsAgeRelative
- Patients with cardiac arrhythmiasCardiovascularRelative
- Pediatric useAgeRelative
Regulatory Status
- European UnionResearchNot authorized for clinical use.
- United StatesResearchInvestigational use only in preclinical studies.
- United KingdomUnapprovedNo MHRA approval; research reagent only.
Not approved for human use; available only for preclinical research.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is GsMtx-4?
GsMTx-4 is a 34‑amino‑acid peptide isolated from the venom of the tarantula Grammostola spatulata. It blocks mechanosensitive ion channels and is used experimentally to study mechanotransduction and as a lead for neuroprotective and cardioprotective therapies.
What is GsMtx-4 used for?
GsMtx-4 is educationally associated with: Muscular dystrophy (Duchenne) treatment, Research tool – mechanotransduction studies, Cardioprotection during ischemia, Atrial fibrillation suppression, Neuroprotection after traumatic brain injury, Neuropathic pain relief, Pulmonary arterial hypertension. Educational only — not medical advice.
How is GsMtx-4 administered?
Recorded routes of administration: Intracerebroventricular, Intraperitoneal, Intrathecal, Intravenous, Subcutaneous, Topical (research).
What are the potential side effects of GsMtx-4?
Reported adverse effects include: Cardiovascular depression, Hypotension, Immune/allergic reaction, Off-target channel inhibition. This list is not exhaustive — consult a qualified clinician.
Who should avoid GsMtx-4?
Recorded contraindications: Known hypersensitivity to spider venom peptides, Pregnancy, Human clinical use. Consult a qualified clinician before use.